Search
01/09/2021
LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology
Garrido, P, Paz-Ares, L, Majem, M, Moran, T, Trigo, JM, Bosch-Barrera, J, Garcia-Campelo, R, Gonzalez-Larriba, JL, Sanchez-Torres, JM, Isla, D, Vinolas, N, Camps, C, Insa, A, Juan, O, Massuti, B, Paredes, A, Artal, A, Lopez-Brea, M, Palacios, J, Felip, E. LungBEAM: A prospective multicenter study to monitor stage IV NSCLC patients with EGFR mutations using BEAMing technology. Cancer Medicine. 2021; 10(17)DOI:10.1002/cam4.4135. PMID:34296539. IF:4.711(Q2/5D).
01/09/2021
Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe
Vokinger, KN, Hwang, TJ, Daniore, P, Lee, CC, Tibau, A, Grischott, T, Rosemann, TJ, Kesselheim, AS. Analysis of Launch and Postapproval Cancer Drug Pricing, Clinical Benefit, and Policy Implications in the US and Europe. JAMA Oncology. 2021; 7(9)DOI:10.1001/jamaoncol.2021.2026. PMID:34196656. IF:33.012(Q1/1D).
01/09/2021
Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors
Moreno, V, Greil, R, Yachnin, J, Majem, M, Wermke, M, Arkenau, HT, Basque, JR, Nidamarthy, PK, Kapoor, S, Cui, XM, Giovannini, M. Pharmacokinetics and safety of capmatinib with food in patients with MET-dysregulated advanced solid tumors. CLINICAL THERAPEUTICS. 2021; 43(6)DOI:10.1016/j.clinthera.2021.04.006. PMID:34053700. IF:3.637(Q2/5D).
01/09/2021
Risk of contagion of SARS-CoV-2 among otorhinolaryngologists in Spain during the "Two waves"
Martin-Villares, C, Bernal-Sprekelsen, M, Molina-Ramirez, CP, Bartolome-Benito, M, Orus, C, Escamilla Carpintero, Yolanda. Risk of contagion of SARS-CoV-2 among otorhinolaryngologists in Spain during the "Two waves". EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY. 2021; 278(9)DOI:10.1007/s00405-020-06582-8. PMID:33464400. IF:3.236(Q2/3D).
01/09/2021
The EHA Research Roadmap: Malignant Myeloid Diseases
Dohner, H, Malcovati, L, Ossenkoppele, GJ, Hochhaus, A, Vannucchi, AM, Bullinger, L, Cervantes, F, Craddock, C, de Witte, T, Dohner, K, Dombret, H, Fenaux, P, Geissler, J, Germing, U, Guilhot, F, Harrison, C, Hellstrom-Lindberg, E, Passamonti, F, Sierra, J, Skoda, R, Wierzbowska, A. The EHA Research Roadmap: Malignant Myeloid Diseases. Hemasphere. 2021; 5(9)DOI:10.1097/HS9.0000000000000635. PMID:34476345. IF:8.300(Q1/2D).
01/09/2021
Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial
Larson, RA, Mandrekar, SJ, Huebner, LJ, Sanford, B, Laumann, K, Geyer, S, Bloomfield, CD, Thiede, C, Prior, TW, Dohner, K, Marcucci, G, Voso, MT, Klisovic, RB, Galinsky, I, Wei, AH, Sierra, J, Sanz, MA, Brandwein, JM, de Witte, T, Niederwieser, D, Appelbaum, FR, Medeiros, BC, Tallman, MS, Krauter, J, Schlenk, RF, Ganser, A, Serve, H, Ehninger, G, Amadori, S, Gathmann, I, Dohner, H, Stone, RM. Midostaurin reduces relapse in FLT3-mutant acute myeloid leukemia: the Alliance CALGB 10603/RATIFY trial. LEUKEMIA. 2021; 35(9)DOI:10.1038/s41375-021-01179-4. PMID:33654204. IF:12.897(Q1/1D).